Artwork

内容由Psychopharmacology Institute提供。所有播客内容(包括剧集、图形和播客描述)均由 Psychopharmacology Institute 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Rethinking Antipsychotic Dosing: Lessons from the RADAR Trial

13:34
 
分享
 

Manage episode 459610226 series 2464201
内容由Psychopharmacology Institute提供。所有播客内容(包括剧集、图形和播客描述)均由 Psychopharmacology Institute 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice.

Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

  continue reading

109集单集

Artwork
icon分享
 
Manage episode 459610226 series 2464201
内容由Psychopharmacology Institute提供。所有播客内容(包括剧集、图形和播客描述)均由 Psychopharmacology Institute 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice.

Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

  continue reading

109集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南

边探索边听这个节目
播放